
Activation domain
DNA
binding
domain
binding site
Reporter Gene

Fig. A


X
Y
Activation domain
DNA
binding
domain
binding site
Reporter Gene

Fig. B


X
A
B
Y
Activation domain
DNA binding domain
binding site
Reporter Gene

Fig. C


X
+
A
B
Y
Activation domain
DNA binding domain
X
A
B
Y
Activation domain
DNA binding domain
binding site
Reporter Gene

Fig. D

Figure 1. Two-hybrid system



Figure. 2. A schematic representation of the Modified three-hybrid system (chemicalhybrid system).



Figure 3: Affinity Labeling Agents

Cox-Aspirin Mechanism



Example of covalent bonding of ligand to the target (Cox-Aspirin mechanism)



R = Dexamethasone; FK-506 or combinatorial compounds n = 0-20

Figure 4: Affinity Labeling Agents

Synthesis of aminoalkyl salicylate



Coupling of aminoalkyl salicyclate to dexamethasone



Figure 5: Affinity Labeling Agents

5a. Penicillins



a. R = PhCH2-

b. R = PhOCH2-

c. R =



d. R =



5b. Cephalosporins/cephamycins



a. R =



X = H

Y =



b. R =



X = OCH3

Y =



c. R =



X = H

Y = Cl

d. R =



X = H

Y = H

Figure 6: Mechanism based-inhibitors

Figure 6a. Vigabatrin



Figure 6b. Eflornithine



Figure 6c: Fluorouracil



Example of covalent bonding of ligand to the target (mechanism-based inhibitor)



R' = dexamethasone, FK-506 or combinatorial compounds

Figure 7: Covalent labeling of recombinant protein in living cells with fluorescein analogs



Figure 8: Biocatalyses: enzyme mediated c-c bond formation



Fru A = fructose 1,6-bisphosphate aldolase